Texas Elects Pro-Cannabis Governor and Senator: Could America’s Biggest Untapped Marijuana Market Finally Open?

Burn After Reading The 30-second intel for operators and investors ⏱ 0:30

Texas elects Democrats Gina Hinojosa as governor, Vikki Goodwin as lieutenant governor and James Talarico to the U.S. Senate, all of whom back regulated adult-use cannabis. The vote does not legalize anything, and the nearest commercial change is the medical expansion from three licenses to 15.

• Operators: Adult-use sales remain illegal and legislation is not guaranteed. The concrete opportunity is medical: 12 conditional selections are pending final DPS due diligence, and new licensees must be operational within 24 months of licensure.
• Investors: Verano, Trulieve, Green Thumb and Cresco hold conditional medical selections, which do not depend on adult-use legalization. The article stresses that legislative details matter more than population, and that hemp's $5.5 billion estimate should not be added to any adult-use projection.
• Do now: Separate Texas exposure into three buckets: medical licensing under HB 46, the hemp market, and a hypothetical adult-use market. Track DPS final-license decisions rather than election headlines.

Short on time? You’re done. Want the numbers?Keep reading ↓

With 31.7 million residents, a hemp industry estimated at $5.5 billion and an expanding but tightly regulated medical cannabis program, Texas is entering a new political chapter. Yet legalization remains uncertain, and the commercial implications will depend on decisions in Austin and Washington.

Texas voters delivered one of the most consequential political shifts in the state’s modern history on November 3, electing Democrats Gina Hinojosa as governor and James Talarico to the U.S. Senate.

A third result may matter just as much for cannabis businesses: Democratic state Rep. Vikki Goodwin defeated incumbent Republican Lt. Gov. Dan Patrick, replacing one of the state’s most influential opponents of marijuana legalization.

All three incoming officials have expressed support for regulated adult-use cannabis, according to the Texas Cannabis Policy Center’s 2026 voter guide.

Their victories create a potentially different political environment in the nation’s second-most-populous state, home to approximately 31.7 million residents and one of the country’s largest markets without legal adult-use marijuana sales.

But the election does not legalize recreational cannabis, expand existing business licenses beyond what current law authorizes, or guarantee that legislation will advance.

Texas already has a medical cannabis program undergoing significant expansion. It also has a multibillion-dollar hemp-derived cannabinoid industry facing tighter regulation and legal uncertainty.

For cannabis companies and investors, understanding the distinction between those markets is essential to evaluating what the election might actually change.

A New Governor, Lieutenant Governor and U.S. Senator

Hinojosa defeated three-term Republican Gov. Greg Abbott, becoming Texas’s first Democratic governor since Ann Richards left office in 1995.

Her campaign focused primarily on affordability, education, health care and government accountability rather than cannabis legalization.

Nevertheless, Hinojosa’s positions on marijuana are considerably more permissive than those of her predecessor.

In the 2026 Texas Cannabis Policy Center voter guide, Hinojosa supported expanding medical cannabis access, reducing penalties for possession, legalizing adult possession and establishing a regulated adult-use market.

The Texas Tribune’s candidate guide also reported that she supported allowing voters to decide on THC regulation.

Those positions indicate support for reform, but they should not be confused with a detailed legalization proposal, a legislative timetable or a commitment to establish a particular licensing framework.

Goodwin’s victory over Patrick could have a more immediate impact on the legislative process.

The Texas lieutenant governor presides over the state Senate, appoints committee members and exercises substantial influence over which legislation advances.

Patrick had been a prominent advocate of restrictions on intoxicating hemp products and an opponent of recreational marijuana legalization.

Goodwin, by contrast, supported all four cannabis reforms evaluated in the Texas Cannabis Policy Center’s voter guide, including adult-use sales.

Her election changes leadership in a chamber that has historically posed significant obstacles to cannabis reform.

However, legislation will still require sufficient support among lawmakers. Republican control of legislative seats, committee negotiations and competing policy priorities could limit the scope of any reforms.

Meanwhile, Talarico’s election to the U.S. Senate gives Texas a federal representative who has explicitly advocated nationwide legalization.

Unlike Hinojosa and Goodwin, however, Talarico will serve in Washington rather than directly oversee Texas cannabis licensing or state legislation.

Talarico Wants to Work With Trump on Marijuana Legalization

Talarico’s position on federal cannabis policy is notable because he has identified legalization as a potential area of cooperation with President Donald Trump.

During an October 20 interview with MS NOW, Talarico expressed his willingness to work with President Donald Trump on federal marijuana legalization and the expungement of cannabis-related criminal records, acknowledging that advancing legislation would require cooperation across party lines.

He said he hoped to cooperate with Trump on marijuana legalization and expungement of cannabis-related criminal records.

Talarico also outlined his policy position in an October questionnaire published by the Texas Tribune.

“In the Senate, I’ll support legalizing marijuana for adults,” he said, proposing regulated and taxed sales to support public safety and health programs.

The possibility of cooperation with Trump deserves attention, but it also requires context.

Trump supported Florida’s unsuccessful 2024 adult-use legalization initiative and has backed certain cannabis reforms. His administration has pursued federal changes involving medical marijuana, including Schedule III treatment for qualifying state-licensed medical activities.

That is not equivalent to a federal commitment to legalize adult-use marijuana nationwide.

Nor has the administration established a comprehensive federal commercial framework allowing interstate recreational cannabis sales.

Talarico’s willingness to cooperate with Trump therefore represents a stated political objective, not evidence that the White House has agreed to advance legalization legislation.

Any federal bill would still need to navigate Congress and receive presidential approval.

For Texas operators, federal changes could affect taxation, banking, investment and compliance obligations. They would not, by themselves, establish a Texas adult-use retail market.

Texas Has 31.7 Million Residents. How Much Cannabis Business Is Already There?

The state’s population is the starting point for evaluating its commercial potential.

According to the U.S. Census Bureau, Texas had an estimated 31,709,821 residents in July 2025, up approximately 8.8% from its 2020 population base.

The state also had nearly 11 million households, more than 1.4 million veterans, and a median household income of approximately $78,476.

Its major metropolitan areas include Houston, Dallas-Fort Worth, San Antonio and Austin, creating geographically distinct consumer markets and substantial logistical challenges for statewide distribution.

Yet population alone cannot establish the value of a future legal cannabis market.

Texas does not currently permit recreational marijuana sales, and its existing medical market operates under eligibility, product, and licensing restrictions that differ substantially from those in mature adult-use states.

The strongest evidence of existing commercial demand comes from two separate sectors: medical cannabis and hemp-derived cannabinoids.

Medical Cannabis: An Expanding but Restricted Market

Texas established its Compassionate Use Program in 2015, initially creating one of the country’s most restrictive medical cannabis systems.

The program has gradually expanded to include additional qualifying conditions, products, and distribution options.

According to figures attributed to the Texas Department of Public Safety and compiled by NORML, approximately 169,058 patients were listed in the medical cannabis registry as of August 1, 2026.

That represents approximately 0.53% of the state’s population.

However, the registry figure should not be interpreted as the number of active, purchasing customers. Registry participation does not establish how frequently patients fill prescriptions or how much they spend.

Texas does not provide a readily comparable public retail sales series equivalent to those published by many adult-use states. Consequently, the current medical cannabis market cannot be reliably valued by multiplying the registry count by assumed annual spending.

Hemp: A Multibillion-Dollar Industry Under Pressure

The hemp-derived cannabinoid market is considerably larger by available estimates.

A 2025 economic analysis prepared by Whitney Economics for the Texas Hemp Business Council estimated approximately $5.5 billion in annual industry revenue, including $4.3 billion in retail sales.

The study also estimated approximately $10.2 billion in total economic activity, 53,300 jobs, $2.1 billion in wages and nearly $268 million in annual state sales tax revenue.

These are industry-commissioned estimates, not audited state cannabis sales figures. They nevertheless illustrate the scale of commercial activity associated with hemp-derived cannabinoids in Texas.

The report also identified more than 8,500 businesses participating in the sector. Importantly, the $5.5 billion estimate should not be added to a hypothetical recreational marijuana market projection. Existing hemp sales may overlap with future regulated cannabis demand, while changes in product availability, taxation, and licensing could shift spending between channels.

A future adult-use program might capture some existing demand rather than generate entirely new consumer expenditure.

What Would a Legal Texas Adult-Use Market Be Worth?

There is no reliable way to assign a single revenue figure to a Texas adult-use market that has not yet been authorized.

The commercial outcome would depend on consumer participation, pricing, taxation, product restrictions, retail density, local regulations, and competition from hemp products and illicit suppliers.

To illustrate the scale without presenting a forecast, the following scenarios apply hypothetical annual spending levels across Texas’s entire population.

Illustrative annual spending per resident	Implied statewide annual sales
$50	$1.59 billion
$100	$3.17 billion
$150	$4.76 billion
$200	$6.34 billion

These calculations are hypothetical mathematical scenarios that use total population, including children and nonconsumers, rather than an estimate of eligible purchasers.

Actual revenue would depend on the structure and performance of a future legal market.

They also do not account for substitution between existing hemp purchases and newly authorized marijuana sales.

For investors, the exercise demonstrates the scale of Texas’s addressable population while highlighting why legislative details matter more than headline population figures.

Fifteen Medical Licenses: Who Is Positioned in Texas Today?

The most immediate commercial opportunity is not recreational legalization. It is the expansion of the existing medical program.

House Bill 46, effective September 1, 2025, authorized the Texas Department of Public Safety to increase the number of licensed medical cannabis dispensing organizations from three to 15.

That represents a fivefold increase in the authorized number of operators.

The three established license holders are:

• Fluent, formerly Cansortium Texas.
• Texas Original, operating under the original Compassionate Cultivation license.
• Goodblend, operated by Surterra Texas.

The expansion has attracted multi-state cannabis operators and other applicants seeking access to the Texas medical market.

Among the nine businesses conditionally selected in the first phase of licensing in December 2025 were:

• Verano Texas, LLC (OTC: VRNO)
• Trulieve TX, Inc. (NYSE: TRLV)
• Texas Patient Access, LLC
• Lonestar Compassionate Care Group, LLC
• Lone Star Bioscience, Inc.
• PC TX OPCO LLC, doing business as PharmaCann
• Texa OP, doing business as TexaRx
• Story of Texas, LLC
• Dilatso, LLC

In April 2026, DPS announced three additional conditional selections:

• GTI Texas, LLC, doing business as RISE Dispensaries (CSE: GTII; OTCQX: GTBIF)
• Texas Medica Collective, LLC
• Cresco Labs Texas, LLC (CSE: CL; OTCQX: CRLBF)

The selections bring the expansion process to 12 conditional applicants, alongside the three original license holders.

However, conditional selection is not the same as a final operating license.

DPS conducts further due diligence, including reviews of financial suitability, litigation history, and regulatory compliance.

The agency also maintains an eligibility list of other applicants, including Village Farms (NASDAQ: VFF), for potential future consideration.

Under HB 46, newly licensed organizations must become fully operational within 24 months of licensure.

For companies such as Verano, Trulieve, Green Thumb Industries and Cresco Labs, Texas therefore represents an identifiable medical market expansion opportunity under existing law.

Their prospects do not depend entirely on recreational legalization.

But commercial returns will depend on final licensing, facility investment, patient enrollment, permitted products, and the economics of serving a geographically large state.

Compliance: What Companies Can Actually Sell in Texas

Texas’s medical program remains materially different from the adult-use and medical frameworks operating in many other states.

The Texas Compassionate Use Program requires patients to be permanent Texas residents with qualifying medical conditions and prescriptions entered by approved physicians into the state’s Compassionate Use Registry.

Qualifying conditions include cancer, epilepsy, post-traumatic stress disorder, multiple sclerosis, chronic pain, traumatic brain injury, and several other serious conditions.

The 2025 expansion added conditions and permitted certain additional administration methods, including specified vaporized products.

However, smoking cannabis remains prohibited.

Medical cannabis products are subject to THC dosage and packaging restrictions. Products generally may not exceed 10 milligrams of THC per dosing unit or one gram of THC per package, and physicians may authorize up to a 90-day supply.

Licensed dispensing organizations must comply with DPS registration, inspection, security, and recordkeeping requirements.

Regulated premises generally must be at least 1,000 feet from schools or daycare centers under applicable program rules.

These requirements shape capital expenditures, distribution strategies and the types of products companies can commercialize.

HB 46 also allows satellite locations, potentially improving distribution efficiency and patient access without creating an unrestricted network of conventional adult-use dispensaries.

Home cultivation is not permitted.

Hemp Regulation Could Be Just as Important as Marijuana Legalization

The new administration will inherit a complicated regulatory environment for hemp-derived THC products.

In 2025, Abbott vetoed legislation that would have broadly prohibited intoxicating hemp products but subsequently directed state agencies to tighten oversight. New rules adopted in 2026 introduced stricter testing, packaging, recordkeeping, and licensing requirements.

According to the Texas Department of State Health Services, annual licensing fees are $10,000 per consumable hemp manufacturing location and $5,000 per retail location, excluding applicable processing fees.

A change in the governor’s office could influence agency appointments, enforcement priorities, and legislative proposals, but existing regulations would remain in effect unless amended or overturned.

Federal legislation adds another challenge. New hemp restrictions, postponed by President Donald Trump to December 11, 2026, could prohibit many intoxicating cannabinoid products, potentially disrupting portions of a Texas hemp industry estimated at $5.5 billion annually.

While restrictions could reduce competition for licensed medical cannabis operators, consumers would still need to meet medical eligibility requirements. Texas’s incoming leadership could pursue state reforms but cannot override federal law, leaving hemp retailers, cannabis operators, and investors facing considerable regulatory uncertainty.

Houston Voters Also Signal Support for Reform

The statewide election was accompanied by a local development in Houston, where voters approved a measure making misdemeanor marijuana possession the lowest possible enforcement priority for local police.

The measure was leading approximately 72% to 28% on election night in Texas’s largest city.

The Investors’ Outlook: Political Change Meets Regulatory Reality

The Texas election creates several distinct developments for cannabis investors.

The medical market is already expanding from three authorized operators to 15, creating opportunities for selected businesses to establish cultivation, processing, and distribution operations.

The hemp sector, estimated by an industry-commissioned study to generate billions of dollars annually, faces regulatory costs and product restrictions that could materially alter its competitive structure.

At the state level, the election of Hinojosa and Goodwin changes the political leadership overseeing legislation and executive agencies.

At the federal level, Talarico has expressed a willingness to work with Trump on cannabis legalization, although no agreement or legislative outcome has been established.

These developments could eventually converge, but they should not be treated as a single coordinated reform process.

Investors will need to monitor the incoming administration’s legislative priorities, the composition of the Texas Legislature, implementation of HB 46, ongoing hemp litigation and federal policy decisions.

The immediate investment case remains tied to businesses with lawful market access, sufficient capital and the ability to operate under Texas’s existing compliance requirements.

A potential adult-use market represents a longer-term opportunity whose size, timing, and regulatory structure remain unknown.

Texas’s population makes it difficult for the cannabis industry to ignore.

The election has made its political future more interesting. Whether that translates into a broader commercial market will depend on the laws and regulations that follow.

The intersection of federal cannabis policy, state licensing, and investment strategy will also be a focus of IgniteIt’s Cannabis Capital & Policy Summit in Washington, D.C., on November 18, where industry leaders and policymakers will examine how regulatory developments are affecting cannabis businesses and capital markets.